Clinical Trials Directory

Trials / Completed

CompletedNCT01528007

Treatment of Pathological Gambling With Naltrexone Pharmacotherapy and Brief Intervention

Treatment of Pathological Gambling With Naltrexone Pharmacotherapy and Brief Intervention - a Placebo Controlled Trial

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
100 (actual)
Sponsor
Finnish Institute for Health and Welfare · Other Government
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The aim of this research is to explore the efficacy of the opiate antagonist, naltrexone as combined with CBT-intervention in the treatment of pathological gambling (PG). The study period is 2011-2014 during which one hundred Pathological Gamblers will be recruited to participate to this placebo-controlled double-blind trial.

Detailed description

All participants have to be able to read and understand the patient information sheet and sign the informed consent. All participants are free to stop being in the study whenever they wanted. The patients are not paid or reimbursed for participation. The study periods is 21 weeks during which the participant's have 8 appointments with the researchers. During the meetings research data will be collected and the participant is having Controlled Behavioral Therapy (CBT) consulting from a trained therapist. At the study visits, the subjects are given written instructions for the proper use of naltrexone and advised to take 50 mg naltrexone approximately one hour before gambling or feeling urges to gamble (and to refrain from taking naltrexone at other times). In this study the maximal daily dose is 50mg of naltrexone. The medication is free for the subjects.

Conditions

Interventions

TypeNameDescription
DRUGNaltrexone pharmacotherapyNaltrexone 50mg when graving to gamble.
DRUGPlaceboPlacebo pill with no active ingredients.

Timeline

Start date
2011-01-01
Primary completion
2013-09-01
Completion
2013-09-01
First posted
2012-02-07
Last updated
2013-12-05

Locations

1 site across 1 country: Finland

Source: ClinicalTrials.gov record NCT01528007. Inclusion in this directory is not an endorsement.